Based on our observation, both PAR1 and its activator serine proteases (all of which are current therapeutic targets in other diseases) may be considered as new therapeutic targets in HAE if further studies involving tissue biopsy can confirm our results. The gene discussed is F2R; the disease is hereditary angioedema.